Ranbaxy Plans to Re-Launch Skincare Brand Sotret in U.S.
India’s largest drug maker Ranbaxy Laboratories plans to re-launch its former flagship skincare brand Sotret (isotretinoin) in the U.S., that has been banned for almost four years, through a marketing partnership with a Canadian firm Cipher Pharmaceuticals.
300 N. Washington St., Suite 200, Falls Church, VA 22046, USA.
Phone (703) 538-7600 - Fax (703) 538-7676 - Toll free (888) 838-5578.
Copyright by FDAnews. All rights reserved. Do not duplicate or redistribute in any form.